1-6 of 6
Mitchell P. Levesque
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy

Nina Zila, Ossia M. Eichhoff, Irene Steiner, Thomas Mohr, Andrea Bileck, Phil F. Cheng, Alexander Leitner, Ludovic Gillet, Tatjana Sajic, Sandra Goetze, Betty Friedrich, Patricia Bortel, Johanna Strobl, René Reitermaier, Sabrina A. Hogan, Julia M. Martínez Gómez, Ramon Staeger, Felix Tuchmann, Sophie Peters, Georg Stary, Mario Kuttke, Adelheid Elbe-Bürger, Christoph Hoeller, Rainer Kunstfeld, Wolfgang Weninger, Bernd Wollscheid, Reinhard Dummer, Lars E. French, Christopher Gerner, Ruedi Aebersold, Mitchell P. Levesque, Verena Paulitschke
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (1): 159–175.
https://doi.org/10.1158/1078-0432.CCR-23-0562
Published: 05 January 2024
View articletitled, Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy
Open the PDF for Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy in another window
Includes: Supplementary data
Journal Articles

Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor

Jürgen Wichmann, Caroline Rynn, Thomas Friess, Jeannine Petrig-Schaffland, Martin Kornacker, Cornelia Handl, Jasmin Emmenegger, Jan Eckmann, Frank Herting, Nicolas Frances, Daniel Hunziker, Daniela Krummenacher, Dominik Rüttinger, Alison Ribeiro, Marina Bacac, Alessandro Brigo, David S. Hewings, Reinhard Dummer, Mitchell P. Levesque, Gabriel Schnetzler, Bruno Martoglio, James R. Bischoff, Piergiorgio Pettazzoni
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (4): 770–780.
https://doi.org/10.1158/1078-0432.CCR-21-2761
Published: 15 February 2022
View articletitled, Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
Open the PDF for Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor in another window
Includes: Supplementary data
Journal Articles

Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibition

Lucas Basler, Hubert S. Gabryś, Sabrina A. Hogan, Matea Pavic, Marta Bogowicz, Diem Vuong, Stephanie Tanadini-Lang, Robert Förster, Ken Kudura, Martin W. Huellner, Reinhard Dummer, Matthias Guckenberger, Mitchell P. Levesque
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (16): 4414–4425.
https://doi.org/10.1158/1078-0432.CCR-20-0020
Published: 14 August 2020
View articletitled, Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibition
Open the PDF for Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibition in another window
Includes: Supplementary data
Journal Articles

A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors

Andrea Aloia, Daniela Müllhaupt, Christophe D. Chabbert, Tanja Eberhart, Stefanie Flückiger-Mangual, Ana Vukolic, Ossia Eichhoff, Anja Irmisch, Leila T. Alexander, Ernesto Scibona, Dennie T. Frederick, Benchun Miao, Tian Tian, Chaoran Cheng, Lawrence N. Kwong, Zhi Wei, Ryan J. Sullivan, Genevieve M. Boland, Meenhard Herlyn, Keith T. Flaherty, Nicola Zamboni, Reinhard Dummer, Gao Zhang, Mitchell P. Levesque, Wilhelm Krek, Werner J. Kovacs
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (22): 6852–6867.
https://doi.org/10.1158/1078-0432.CCR-19-0253
Published: 15 November 2019
View articletitled, A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors
Open the PDF for A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors in another window
Includes: Supplementary data
Journal Articles

Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL

Sima Rozati, Phil F. Cheng, Daniel S. Widmer, Kazuyasu Fujii, Mitchell P. Levesque, Reinhard Dummer
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (8): 2020–2031.
https://doi.org/10.1158/1078-0432.CCR-15-1435
Published: 14 April 2016
View articletitled, Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL
Open the PDF for Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL in another window
Journal Articles

Hedgehog Pathway Inhibitors Promote Adaptive Immune Responses in Basal Cell Carcinoma

Atsushi Otsuka, Jil Dreier, Phil F. Cheng, Mirjam Nägeli, Holger Lehmann, Lea Felderer, Ian J. Frew, Shigeto Matsushita, Mitchell P. Levesque, Reinhard Dummer
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (6): 1289–1297.
https://doi.org/10.1158/1078-0432.CCR-14-2110
Published: 12 March 2015
View articletitled, Hedgehog Pathway Inhibitors Promote Adaptive Immune Responses in Basal Cell Carcinoma
Open the PDF for Hedgehog Pathway Inhibitors Promote Adaptive Immune Responses in Basal Cell Carcinoma in another window
Includes: Supplementary data